To include your compound in the COVID-19 Resource Center, submit it here.

DBV's peanut allergy therapy meets Phase III safety endpoint

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Viaskin Peanut (DBV-712) met the primary safety endpoint in the Phase III REALISE trial to treat peanut allergy in patients ages 4-11.

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE